We are live on ! Find out more
Cambridge Investment Research Advisors

Cambridge Investment Research Advisors Portfolio holdings

AUM $44.6B
1-Year Est. Return 28.94%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+28.94%
3 Year Est. Return
+82.62%
5 Year Est. Return
+90.41%
10 Year Est. Return
+293.66%
AUM
$26B
AUM Growth
+$2.52B
Cap. Flow
+$734M
Cap. Flow %
2.83%
Top 10 Hldgs %
21.08%
Holding
3,430
New
246
Increased
1,548
Reduced
1,426
Closed
128

Sector Composition

Rank Sector Weight
1 Technology 10.99%
2 Financials 5.01%
3 Consumer Discretionary 4.04%
4 Healthcare 3.7%
5 Industrials 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STEM icon
3201
Stem
STEM
$48.8M
$59K ﹤0.01%
1,342
-309
-19% -$17.2K
GPMT
3202
Granite Point Mortgage Trust
GPMT
$58.8M
$58K ﹤0.01%
12,058
-3,942
-25% -$20.5K
DSX icon
3203
Diana Shipping
DSX
$296M
$56K ﹤0.01%
19,345
+4,195
+28% +$12.5K
CLNE icon
3204
Clean Energy Fuels
CLNE
$384M
$55K ﹤0.01%
20,531
-1,475
-7% -$4.4K
NNDM
3205
Nano Dimension
NNDM
$343M
$55K ﹤0.01%
19,626
-1,814
-8% -$4.67K
FCEL icon
3206
FuelCell Energy
FCEL
$1.73B
$54K ﹤0.01%
1,506
-34
-2% -$1.25K
ACRS icon
3207
Aclaris Therapeutics
ACRS
$860M
$52K ﹤0.01%
41,873
MIN
3208
Aberdeen Intermediate Income Fund
MIN
$281M
$52K ﹤0.01%
19,729
-4,779
-19% -$13K
OMER icon
3209
Omeros
OMER
$992M
$51K ﹤0.01%
14,743
+600
+4% +$2.28K
SABA
3210
Saba Capital Income & Opportunities Fund II
SABA
$222M
$51K ﹤0.01%
6,724
-31,437
-82% -$240K
VBIV
3211
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$51K ﹤0.01%
84,082
-4,312
-5% -$2.64K
SBSW icon
3212
Sibanye-Stillwater
SBSW
$7.58B
$50K ﹤0.01%
+10,657
New +$49K
SPCE icon
3213
Virgin Galactic
SPCE
$500M
$50K ﹤0.01%
1,673
+428
+34% +$15.5K
TSHA icon
3214
Taysha Gene Therapies
TSHA
$2.05B
$50K ﹤0.01%
+17,290
New +$36K
SLI
3215
Standard Lithium
SLI
$594M
$49K ﹤0.01%
41,521
-5,100
-11% -$6.99K
EVGO icon
3216
EVgo
EVGO
$497M
$47K ﹤0.01%
18,911
-2,162
-10% -$5.61K
PACB icon
3217
Pacific Biosciences
PACB
$345M
$45K ﹤0.01%
11,934
-90,867
-88% -$532K
REKR icon
3218
Rekor Systems
REKR
$94M
$45K ﹤0.01%
19,595
-569
-3% -$1.57K
SGMA
3219
DELISTED
Sigmatron International
SGMA
$45K ﹤0.01%
12,500
TRIB
3220
Trinity Biotech
TRIB
$7.86M
$45K ﹤0.01%
743
DHF
3221
BNY Mellon High Yield Strategies Fund
DHF
$175M
$44K ﹤0.01%
18,162
+229
+1% +$536
DNA icon
3222
Ginkgo Bioworks
DNA
$486M
$44K ﹤0.01%
957
+13
+1% +$673
MVIS icon
3223
Microvision
MVIS
$111M
$44K ﹤0.01%
1,599
-8
-0.5% -$272
ONL
3224
Orion Office REIT
ONL
$161M
$43K ﹤0.01%
12,169
-730
-6% -$3.28K
PZG icon
3225
Paramount Gold Nevada
PZG
$130M
$43K ﹤0.01%
105,648
-16,102
-13% -$5.88K

Similar funds

Cambridge Investment Research Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Cambridge Investment Research Advisors held 3,430 positions worth $26B, up 11% from $23.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Cambridge Investment Research Advisors's Q1 2024 filing shows 246 new, 1,548 increased, 1,426 reduced and 128 closed positions. Its largest new stake was Polen Capital International Growth ETF: 1,886,311 shares worth $18.9M. The largest sale was Apple, an estimated $25M.

By sector, the portfolio is most concentrated in Technology at 11% of assets, up from 11% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Cambridge Investment Research Advisors's largest Q1 2024 buy was Polen Capital International Growth ETF: 1,886,311 shares worth $18.9M.
  • Cambridge Investment Research Advisors added most to Vanguard Total Bond Market in Q1 2024, an estimated $25.4M increase.
  • Cambridge Investment Research Advisors's biggest Q1 2024 reduction was Apple, cutting an estimated $25M.
  • Cambridge Investment Research Advisors fully exited iMGP RBA Responsible Global Allocation ETF in Q1 2024, selling an estimated $3.97M.
  • Cambridge Investment Research Advisors's ten largest holdings make up 21% of its $26B portfolio in Q1 2024.
  • Cambridge Investment Research Advisors opened 246 new positions and closed 128 in Q1 2024.
  • Cambridge Investment Research Advisors's portfolio value rose 11% quarter-over-quarter to $26B.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.